Cardio Diagnostics Holdings Inc. Targets Precision Cardiology with Multi-Omic AI Platform

Cardio Diagnostics Holdings (NASDAQ: CDIO) is positioned at the forefront of a transformation in cardiovascular diagnostics, where advances in molecular science and artificial intelligence (AI) are converging to deliver more precise, individualized insights from minimally invasive tests. The company is developing a proprietary platform that integrates epigenetic and genetic biomarkers with AI to generate personalized cardiovascular risk assessments from a simple blood sample.

At the core of Cardio Diagnostics’ approach is the use of AI to integrate multi-omic data, specifically epigenetic markers such as DNA methylation with genetic information, to provide a more comprehensive view of cardiovascular health. Traditional diagnostic tools often rely on population-based risk factors such as cholesterol levels, blood pressure and family history. While these indicators are valuable, they may not fully capture individualized disease risk or early molecular changes of disease that precede clinical symptoms. By contrast, epigenetic biomarkers reflect how environmental and lifestyle factors influence gene expression, offering a dynamic layer of insight that evolves over time.

Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary artificial intelligence-driven Integrated Genetic-Epigenetic Engine (Core Technology) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease.

For more information, visit https://ibn.fm/qlTzE.